Long-term efficacy of rasagiline in early Parkinson's disease

International Journal of Neuroscience

Volumn 120, Issue 6, 2010, Pages 404-408

  Lew, Mark F ^a   Hauser, Robert A ^b   Hurtig, Howard I ^c   Ondo, William G ^d   Wojcieszek, Joanne ^e   Goren, Tamar ^f   Fitzer Attas, Cheryl J ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c PENNSYLVANIA HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TEVA PHARMACEUTICALS   (Israel)

Author keywords

Dopamine agonists; Efficacy; Levodopa; Long term; Monotherapy; Rasagiline

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; RASAGILINE;

ACCIDENTAL INJURY; ADJUVANT THERAPY; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; INFECTION; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MELANOMA; MONOTHERAPY; NAUSEA; PARKINSON DISEASE; SIDE EFFECT; SYNCOPE; TREATMENT DURATION;

ANTIPARKINSON AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DOPAMINE AGENTS; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; INDANS; KAPLAN-MEIERS ESTIMATE; LEVODOPA; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952848015     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207451003778744     Document Type: Article

References (12)

1. Aminoff, M. J. (2006). Treatment should not be initiated too soon in Parkinson's disease. Annals of Neurology, 59, 562-564.
2. Clarke, C. E. (2008). Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Movement Disorders, 23, 784-789.
3. Happe, S., & Berger, K. (2001). The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease-a prospective study. Journal of Neurology, 248, 1062-1067.
4. Hauser, R. A., Lew, M. F., Hurtig, H. I., Ondo,W. G.,Wojcieszek, J., & Fitzer-Attas, C. J. (2009). Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Movement Disorders, 24, 564-573.
5. Miyasaki, J. M.,Martin, W., Suchowersky, O.,Weiner, W. J., & Lang. A. E. (2002). Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the quality standards subcommittee of the American academy of neurology. Neurology, 58, 11-17.
6. Nirenberg, M. J., &Waters, C. (2006). Compulsive eating and weight gain related to dopamine agonist use. Movement Disorders, 21, 524-529.
7. O'Sullivan, S. S., Evans, A. H., & Lees A.J. (2009).Dopamine dysregulation syndrome: An overview of its epidemiology, mechanisms and management. CNS Drugs, 23, 157-170.
8. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Archives of Neurology, 59, 1937-1943.
9. Parkinson Study Group. (2004). A controlled, randomized, delayedstart study of rasagiline in early Parkinson disease. Archives of Neurology, 61, 561-566.
10. Schapira, A. H. V., & Obeso, J. (2006). Timing of treatment initiation in Parkinson's disease: A need for reappraisal? Annals of Neurology, 59, 559-562.
11. Voon, V., Hassan, K., Zurowski, M., de Souza, M., Thomsen, T., Fox, S., et al. (2006). Prevalence of repetitive and rewardseeking behaviors in Parkinson disease. Neurology, 67, 1254-1257.
12. Weintraub,D., Siderowf, A.D., Potenza,M.N., Goveas, J., Morales, K. H., Duda, J. E. et al. (2006). Association of dopamine agonist use with impulse control disorders in Parkinson disease. Archives of Neurology, 63, 969-973.